Tag:
NHS
Latest Headlines
Latest Headlines
Covance teams with U.K.'s NHS Trust on Phase I trials
Covance has formed an alliance with Royal Liverpool and Broadgreen University Hospitals NHS Trust to conduct early clinical trials for biotech and pharma clients.
U.K.'s NHS considers commercial services; Big Pharma intrigued
In a move to generate revenue in a down economy, the U.K.'s National Health Service is planning to offer its services abroad, looking to work with international CROs, pharma companies and healthcare providers.
U.K. drug costs drop as blockbusters go off patent
On the heels of news that drug spending in the U.S. rose last year, the U.K. reports a decline in its pharma costs, thanks to blockbuster medications that lost patent protection.
NICE eyes NHS formularies for excluded drugs
The U.K.'s cost-effectiveness watchdog doesn't want its advice to go unheeded. The National Institute for Health and Clinical Excellence will review National Health Service formularies, which vary
Will NHS use of Avastin spark a price cut for Lucentis?
The ongoing saga of Roche's eye drug Lucentis and its involuntary competition with sister drug Avastin has taken a new turn. Regional officials with the U.K.'s National Health Service are approving
NHS overspent on modern insulins, BMJ suggests
In this austerity-minded era, the idea that a government might be overspending on drugs catches a lot of attention--especially if that spending might be unnecessary. So, expect a new study from the
U.K. accuses Servier of generic-blocking, sues for £220M
The pay-for-delay battle is now in U.K. court. Health Secretary Andrew Lansley has sued the French drugmaker Servier for £220 million ($361.3 million), claiming that the company blocked generic
NHS trusts restrict drug access to cut costs
Like many government health programs, the UK's National Health Service has been fighting budget shortfalls. Unlike private insurers, the NHS makes news whenever it cuts benefits. And unfortunately
Roche's Avastin rejected by NICE for colon cancer
Roche has failed to get the cancer drug Avastin on the National Health Service formulary for colorectal-cancer treatment. The U.K.'s cost-effectiveness watchdog nixed Roche's bid for NHS use, saying
U.K. doc says GPs don't want NICE's job
Even top brass at the U.K.'s cost-effectiveness watchdog were caught flat-footed by news that their agency would be sidelined when government reformers fully implement their overhaul of the National
